Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Prazosin or Propranolol with Brexpiprazole/Sertraline on Blood Pressure
NCT05189977Phase 1Terminated
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Sep 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brexpiprazole orally disintegrating tablet in post-traumatic stress disorder (PTSD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Changes in Blood Pressure and Heart Rate between control and treatment periods, Maximum change in Systolic Blood Pressure from supine to standing at 21 days and 2 more. Started Sep 2022; status: terminated.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05189977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189977.